Clinical trials: Castrate-resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This partially randomized phase I/II trial studies the side effects and how well sirolimus works when given together with docetaxel and carboplatin in treating patients with castration-resistant prostate cancer that has spread to…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7, Metastatic Malignant Neoplasm in the Bone
- Trial name
- NCT02565901
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Prostate Cancer
Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy
The purpose of this study is to test the safety of ketoconazole and how well it works after chemotherapy has been used. Ketoconazole at lower doses has been used for fungal infections however has not yet been approved by the Food…
- Trial name
- NCT00895310
- Testing
- Ketoconazole, Hydrocortisone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Metastatic Castration-resistant Prostate Cancer
Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
Taxotere is the current standard first-line chemotherapy for mCRPC and may be used as second-line therapy in good responders in first-line (Taxotere rechallenge).
- Trial name
- CABA-DOC (NCT02044354)
- Testing
- Taxotere, Jevtana
- Where
- France
- Volunteers
- 195 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
The primary objectives of this study are to evaluate the safety and tolerability of opevesostat in the treatment of male Chinese participants with metastatic castration-resistant prostate cancer (mCRPC) and to characterize the…
- Trial name
- NCT06136598
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone
- Where
- 3 sites in China
- Volunteers
- 14 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
The purpose of this study is to assess the efficacy of a PARP inhibitor, Pamiparib, in metastatic castration-resistant prostate cancer patients with homologous recombination deficiency or BRCA 1 or 2 somatic/germline mutation.
- Trial name
- NCT05327621
- Testing
- Pamiparib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Cancer of the Prostate
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer
The main aim of this trial is to assess the response rate, the feasibility and toxicity of the treatment with antigen loaded Dendritic Cell Vaccination in Prostate Cancer patients.
- Trial name
- NCT01897207
- Testing
- Dendritic cell application
- Volunteers
- 15 people
- Sponsor
- Cantonal Hospital of St. Gallen
Prostate Cancer
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293371
- Testing
- docetaxel, prednisone, vatalanib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Cutaneous Squamous Cell Carcinoma
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
- Trial name
- NCT06567314
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Castration-resistant Prostate Cancer
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
This is a randomized, multi-center, double-blind, Phase III study of radium-223 plus enzalutamide or darolutamide compared to enzalutamide or darolutamide treatment plus placebo.
- Trial name
- ESCALATE (NCT04237584)
- Testing
- Enzalutamide during Lead-in Period, Lead-in Enzalutamide followed by Radium-223/Enzalutamide, Darolutamide during Lead-in Period
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- MANA RBM
mCRPC or Advanced/Metastatic Solid Tumors
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
- Trial name
- NCT07533708
- Testing
- HLX3902
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic Castration-Resistant Prostate Cancer
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, non-randomized, Phase I, dose escalation/dose expansion study of PCUR-101 in combination with androgen suppression therapy in the patients with metastatic CRPC
- Trial name
- NCT03137758
- Testing
- PCUR - 101
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Pellficure Pharmaceuticals, Inc
Metastasis Castration Resistant Prostate Cancer(mCRPC)
ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06001255
- Testing
- HS-20093
- Where
- 15 sites in China
- Volunteers
- 120 people
- Sponsor
- Hansoh BioMedical R&D Company
Prostate Cancer
Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
Hypothesis: Treatment with Burixafor hydrobromide will effectively mobilize metastatic prostate cancer (PCa) cells (i.e. disseminated tumor cells; DTCs) into the blood from the bone marrow.
- Trial name
- NCT02478125
- Testing
- Burixafor Hydrobromide, Docetaxel, G-CSF
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Castrate-resistant Metastatic Prostate Cancer
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Cabazitaxel is already approved by the Food and Drug Administration (FDA) for use in patients with advanced prostrate cancer, following docetaxel therapy.
- Trial name
- NCT01750866
- Testing
- Cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF)
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and…
- Trial name
- NCT02518698
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- United States
- Volunteers
- 1,163 people
- Sponsor
- Bayer
Prostate Carcinoma, Castration-resistant Prostate Cancer
Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic
This study compares the biological activity of cabazitaxel (6 cycles) to that of docetaxel (6 cycles) in metastatic castrate-resistant prostate cancer (mCRPC) patients with docetaxel resistant mCRPC defined as ≥5 circulating…
- Conditions
- Prostate Carcinoma, Castration-resistant Prostate Cancer, Circulating Tumor Cells, Chemotherapy
- Trial name
- TACTIK (NCT03101046)
- Testing
- Cabazitaxel, Docetaxel
- Where
- 5 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Primary Disease, Prostate Cancer
Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer
The purpose of the trial is to determine the most effective dose of BAy 46-9003 associated to taxotere for first-line treatment of patient with prostatic cancer.
- Trial name
- NCT00405210
- Testing
- sorafenib (200 or 400mg bid) and taxotere iv
- Where
- 6 sites in Belgium, France
- Volunteers
- 38 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Castration-resistant Prostate Cancer, Bone Metastases
The Combination Therapy With Ra-223 and Enzalutamide
This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis
- Trial name
- CORE-OCU (NCT03305224)
- Testing
- Ra-223 in combination with enzalutamide
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Taro Iguchi, MD, PHD
Prostate Adenocarcinoma
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Cabozantinib (XL184) is a new drug that is being developed to treat cancer. Cabozantinib works by blocking the "angiogenesis," or the growth of new blood vessels, to the tumor.
- Trial name
- NCT01347788
- Testing
- cabozantinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.